Clinical Trials Logo

Cystic Fibrosis clinical trials

View clinical trials related to Cystic Fibrosis.

Filter by:

NCT ID: NCT03437811 Recruiting - Clinical trials for Cystic Fibrosis, Pulmonary

Airway Clearance System (K031876) Phase IV Device Efficacy

Start date: February 22, 2018
Phase: N/A
Study type: Interventional

Phase IV interventional study of adults (18 to 55) having a diagnosis of cystic fibrosis (mild, moderate or severe). The study is completely voluntary and is designed to measure participants use and the effectiveness of the device within the 510K indication of: airway clearance therapy when external manipulation of the thorax. The trial period shall be 30 days and include use of a FDA cleared pulse oximetry monitor (K131111), manual spirometer as well as completion of semi-weekly participant survey.

NCT ID: NCT03435939 Not yet recruiting - Cystic Fibrosis Clinical Trials

Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240

Start date: March 10, 2018
Phase: Early Phase 1
Study type: Interventional

The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies

NCT ID: NCT03434886 Completed - Cystic Fibrosis Clinical Trials

Outcomes in CF Patients Accessing Their Registry Health Records

Start date: March 2016
Phase: N/A
Study type: Interventional

A multifactorial, parallel group, randomised control study in cystic fibrosis (CF) patients aged 13-30 years over an 18 month period. Patients will be offered read-only access to their CF registry electronic health record (CF View), or educational videos on CF (videos), or videos and CF View, or usual standard of care. The study aims are to examine the effect of patient access to C View on a range of clinical outcomes, health service usage, health literacy and patient reported outcomes.

NCT ID: NCT03424486 Not yet recruiting - Cystic Fibrosis Clinical Trials

Prevalence and Impact of Depression and Anxiety in Cystic Fibrosis

Start date: February 2018
Phase: N/A
Study type: Observational

The Impact of cystic fibrosis (CF) on psychological and emotional functioning has been the focus of several studies over the past 20 years (Patterson et al., 1993). The results from a current meta-analysis indicated that depressed patients were three times more likely to be noncompliant with treatment recommendations than nondepressed patients with chronic illness (DiMatteo et al., 2000). To date, most studies of the prevalence of psychiatric symptoms have been limited by small sample size; reliance on samples of convenience that are potentially biased in term of rates of symptomatology, and measures that contain legitimate symptoms that are part of the respondent's chronic disease (Quittner, 2000). Estimating the prevalence of depression and anxiety has become important as new evidence indicates that these symptoms may have a significant impact on health outcomes, including adherence to medical treatments, utilization of health care services, and rates of morbidity and mortality. More depressive the symptoms are associated with poorer lung function (Riekert et al., 2004; 2005), and that in the absence of depression, poor lung function is minimally associated with lower patient ratings of quality of life. The purpose of the current study is to estimate the regional, and if possible the national prevalence of depressive and anxious symptoms in children and adults with CF and parents caregivers. Patients with CF ages 14 to 17, and parents of children ages 14 to 17, will complete and depression/anxiety screening measure at a routine clinic visit. These will then be linked with demographic and medical variables reported to the CF registry and analyzed cross sectionally. Adults with CF ages 18 and older will also complete the depression / anxiety screening measure at a routine clinic visit. Efforts will be made to recruit a representative sample of patients from each clinic.

NCT ID: NCT03424252 Active, not recruiting - Cystic Fibrosis Clinical Trials

An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects

Start date: December 18, 2017
Phase: Phase 1
Study type: Interventional

Two parts, two periods, crossover study with part 2 is optional. In both parts, subjects will be randomized to sequentially receive both sublingual and oral formulations of FDL169.

NCT ID: NCT03423576 Completed - Cystic Fibrosis Clinical Trials

Effects of a Comprehensive Patient-centered Health Service in Cystic Fibrosis (VEMSE-CF)

Start date: August 1, 2011
Phase: N/A
Study type: Interventional

For the Project VEMSE-CF, a comprehensive patient-centered outpatient health service model was developed offering focused interventions in different areas. These included patient education, as well as nutritional and exercise counselling. Special emphasis was given to the psycho-social services. The implementation was supported by a case manager. The model was implemented in three German CF-Centers. For evaluation, Patient data from 13 additional German CF-Centers offering standard care was used as comparison. In total, 153 patients in the Intervention Group and 163 control patients aged 5-52 years contributed data. The primary endpoint was the number of BMI- and FEV1-measurements over 24 months. Secondary endpoints included mortality, lung transplantation, FEV1, BMI, adherence to therapy, Quality of life, and mental stress.

NCT ID: NCT03421366 Not yet recruiting - Cystic Fibrosis Clinical Trials

Modified Release Posaconazole in Patients With Cystic Fibrosis

Start date: February 5, 2018
Phase: N/A
Study type: Observational

A prospective single center observational cohort of patients with cystic fibrosis to determine whether adequate serum levels of posaconazole, after administration of the newer modified release once daily oral formulation, can be achieved.

NCT ID: NCT03420209 Active, not recruiting - Cystic Fibrosis Clinical Trials

The Effect of Proprioceptive Neuromuscular Facilitation (PNF) Technique for Children With Chronic Pulmonary Diseases.

Start date: December 1, 2016
Phase: N/A
Study type: Interventional

Cystic fibrosis and bronchiectasis are the most seen problems in children with chronic pulmonary diseases. İt is a genetic, chronic system disease that reduces life expectancy, and life quality as well. Chronic lung disease , malnutrition, and reduced activity, caused by disease lead to postural disorders. Muscle force, endurance, activity of Daily living are adversely affected. İn the treatment pulmonary rehabilitation are using. Airway clearance technique, pulmonary exercises, upper extremity ergometer, dumbbells, elastic bands, proprioceptive neuromuscular facilitation technique are applying. Resistance training using elastic bands has become an increasingly common intervention aiming to improve function by increasing muscular strength. İn one study indicated that muscle strength can be improved through three dimensional spiral large scale resistive exercises using proprioceptive neuromuscular facilitation. İn the literature there isn't any research , uses elastic bands with proprioceptive neuromuscular facilitation for the upper extremity and evaluating pulmonary functions, posture, quality of life, muscle force. The aim of this study is giving exercises programme with proprioceptive neuromuscular facilitation and elastic bands and to evaluate pulmonary muscle force, pulmonary functions, posture, activity of daily living, quality of life, functional capacity. And to evaluate the effect of treatment programme on these parameters. The subjects were divided in two groups. An experimental group three times a week for 12 weeks will perform proprioceptive neuromuscular facilitation exercises with elastic bands, and pulmonary exercises. The control group will apply only pulmonary exercises at home programme.

NCT ID: NCT03391414 Completed - Cystic Fibrosis Clinical Trials

Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis

Start date: August 2014
Phase: Phase 1
Study type: Interventional

This study will compare the use of inhaled concentrated sodium chloride solution to an inhaled solution of sodium bicarbonate in an attempt to decrease the thickness and stickiness of the mucus in the lungs of a person with cystic fibrosis. Also, this study is also looking at whether or not it is possible to decrease the acidity of the airways by inhaling sodium bicarbonate through nebulizer treatments.

NCT ID: NCT03390985 Completed - Cystic Fibrosis Clinical Trials

Canadian Observation Trial in CF Patients Undergoing Treatment With Ivacaftor

Start date: April 23, 2013
Phase: N/A
Study type: Observational

Specific aims: 1. To elucidate the biological mechanism that leads to pulmonary and nutritional improvement in CF patients following treatment with ivacaftor using advanced techniques to assess changes of the pulmonary and nutritional status 2. To examine the relation between the individual response to ivacaftor and the presence of modifier genes associated with CF disease severity, 3. To assess altered CFTR function using new available in vivo tests, 4. To validate newly developed in vivo sweat tests with well established functional tests, 5. To establish correlation between the CFTR response to Vx-770 measured in a new ex vivo method (organoids) and the actual clinical and/or functional response in individual patients, 6. To examine response in other CF-specific features such as aqua wrinkling. 7. To examine if sleep/activity level changes. 8. To establish a biorepository to enable further investigations.